echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Eli Lilly's CDK4/6 inhibitor receives FDA approval for the first time to treat early-stage breast cancer

    Eli Lilly's CDK4/6 inhibitor receives FDA approval for the first time to treat early-stage breast cancer

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Eli Lilly (Eli Lilly and Company) announced that the US FDA has approved the CDK4/6 inhibitor Verzenio (abemaciclib) for extended indications, combined with endocrine therapy (tamoxifen or aromatase inhibitors), and adjuvant treatment of hormone receptors.


    Breast cancer has surpassed lung cancer as the most common cancer in the world, with approximately 2.


    This approval is based on an open-label, phase 3 clinical trial of patient subgroup analysis results


    The analysis of this patient subgroup showed that Verzenio combined with endocrine therapy reduced the risk of relapse by approximately 36% compared with endocrine therapy alone (HR=0.


    Verzenio (abemaciclib) is a CDK4/6 inhibitor


    Reference materials:

    [1] FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.